1篇
您的检索式：作者名="Fengjiang Qu"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Clinical evaluation of the first domestically produced generic isosulfan blue injection in sentinel lymph node biopsy for early breast cancer in China:a multicenter,single-arm,open validation trial(CSBrS-024)显示文摘In 2020,the first generic isosulfan blue product for injection(notification number:2020 LP00901,batch number:118210301,5 mL:50 mg,Guangdong Hebo Pharmaceutical Co.,Ltd.)was approved by the National Medical Products Administration of China.This multicenter,single-arm,phase III,open clinical validation trial was organized by the Chinese Society of Breast Surgery to evaluate the efficacy and safety of this domestically produced generic isosulfan blue injection for sentinel lymph node biopsy(SLNB)in patients with early breast cancer(BC)in China. | Fengjiang Qu Di Wu Yunjiang Liu Wei Gao Shu Wang Siyuan Wang Feng Jin Bo Chen Jian Huang Shanshan Sun Zhimin Fan Chinese Society of Breast Surgery | 2022 | Chinese Medical Journal2022，，14： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员